InsidersTradesSigma
Enhabit, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Enhabit, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Enhabit, Inc. has logged 198 insider filings. Market capitalisation: €706.9m. The latest transaction was disclosed on 15 May 2026 (Disposition). Among the most active insiders: Bolton Jeffrey. Every trade is openly available.
198
Insider Decl.
0
Thresholds
€2m
29 ops.
Buy Volume
€35m
44 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Enhabit, Inc. Hold (neutral), based on 5 analysts. Average price target: US$13.80.
47Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 17,428 of 25,927 companies
40.5
score / 100
Value48
Quality33
FCF yld9.3%
Earn yld-0.7%
EV/EBITDA15.0x
ROE-0.2%
Gross mgn49%
Net mgn-0.4%
Debt/EBITDA6.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 May 2026
Declarations198 total
58,560 shares@ US$13.800.15% mcap16.4% of flowCommon StockSEC:0001966580-26-000008:1
34,413 shares@ US$13.800.087% mcap9.6% of flowCommon StockSEC:0001966580-26-000008:2
34,413 shares@ US$13.800.087% mcap9.6% of flowCommon StockSEC:0001966580-26-000008:3
49,601 shares@ US$13.800.13% mcap13.9% of flowCommon StockSEC:0001966580-26-000008:4
49,601 shares@ US$13.800.13% mcap13.9% of flowCommon StockSEC:0001966580-26-000008:5
24,072 shares@ US$13.800.061% mcap6.7% of flowCommon StockSEC:0001966580-26-000008:6
24,072 shares@ US$13.800.061% mcap6.7% of flowCommon StockSEC:0001966580-26-000008:7
48,000 shares@ US$13.800.12% mcap28.2% of flowCommon StockSEC:0001925331-26-000007:1
80,682 shares@ US$13.800.20% mcap47.5% of flowCommon StockSEC:0001925331-26-000007:2
51,148 shares@ US$13.800.13% mcap75.3% of flowCommon StockSEC:0001937414-26-000002:1
73,412 shares@ US$13.800.19% mcap70.9% of flowCommon StockSEC:0001122124-26-000006:1
64,605 shares@ US$13.800.16% mcap71.1% of flowCommon StockSEC:0001205444-26-000007:1
70,338 shares@ US$13.800.18% mcap67.8% of flowCommon StockSEC:0001328255-26-000006:1
60,466 shares@ US$13.800.15% mcap59.3% of flowCommon StockSEC:0001335234-26-000006:1
69,305 shares@ US$13.800.18% mcap61.9% of flowCommon StockSEC:0001653488-26-000006:1
65,964 shares@ US$13.800.17% mcap2.9% of flowCommon StockSEC:0001691132-26-000006:1
127,129 shares@ US$13.800.32% mcap5.6% of flowCommon StockSEC:0001691132-26-000006:2
263,237 shares@ US$13.800.67% mcap11.6% of flowCommon StockSEC:0001691132-26-000006:3
263,237 shares@ US$13.800.67% mcap11.6% of flowCommon StockSEC:0001691132-26-000006:4
340,530 shares@ US$13.800.86% mcap15.1% of flowCommon StockSEC:0001691132-26-000006:5
340,530 shares@ US$13.800.86% mcap15.1% of flowCommon StockSEC:0001691132-26-000006:6
23,575 shares@ US$13.800.060% mcap50.0% of flowCommon StockSEC:0001933994-26-000009:0
7,325 shares@ US$13.800.019% mcap50.0% of flowCommon StockSEC:0001205444-26-000007:0
41,263 shares@ US$13.800.10% mcap100.0% of flowCommon StockSEC:0001966580-26-000008
15,000 shares@ US$13.800.038% mcap50.0% of flowCommon StockSEC:0001335234-26-000006:0
25 of 198 declarations
About Enhabit, Inc.
Enhabit, Inc. is a United States-based healthcare company listed on the NYSE under the ticker EHAB. Headquartered in Dallas, Texas, Enhabit operates in the home health and hospice care market, a segment supported by long-term demographic and reimbursement trends in the U.S. The company was founded in 1998 and became an independent public company on July 1, 2022, following its separation from Encompass Health Corporation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000018/ehab-20251231.htm?utm_source=openai)) Enhabit’s business model is built around two core service lines. Its home health segment provides clinical care delivered in patients’ homes, including recovery support after surgery, disease and injury management, chronic care monitoring, and coordinated therapy services. Its hospice segment focuses on comfort-oriented end-of-life care, offering medical, emotional, and spiritual support to terminally ill patients and their families. Together, these businesses give Enhabit exposure to a broader continuum of home-based care, which is increasingly favored by patients, providers, and payers seeking lower-cost alternatives to inpatient settings. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai)) From a geographic standpoint, the company has a nationwide footprint across 34 states. Enhabit emphasizes its broad network of home health and hospice locations, which helps it maintain referral relationships with hospitals, physicians, health plans, and other care partners. The business relies on local clinical teams, operational density, and technology-enabled care delivery to support patient outcomes and service quality at scale. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai)) In competitive terms, Enhabit is positioned as a scaled national provider in a fragmented industry that includes regional agencies, private operators, and larger healthcare systems expanding into home-based care. Its differentiation lies in its focused specialty in home health and hospice, its national reach, and its ability to manage two complementary service lines under one platform. The company also highlights its patient-centric culture and clinical expertise as key parts of its market positioning. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai)) Recent developments have been important for equity investors. In 2025 and again in March 2026, Enhabit reported improving revenue, patient census, and Adjusted EBITDA, alongside efforts to strengthen free cash flow and the balance sheet. Most notably, on January 23, 2026, the company announced a definitive agreement to be acquired by Kinderhook Capital for $13.80 per share in cash, implying an enterprise value of about $1.1 billion. This transaction is the defining near-term corporate event for Enhabit and a major factor for evaluating the stock on the NYSE in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000015/q42025enhabitearningsrelea.htm?utm_source=openai))
